370 related articles for article (PubMed ID: 27422273)
1. Prognostic Role of Programmed Death Ligand-1 Expression in Breast Cancer: A Systematic Review and Meta-Analysis.
Li X; Li M; Lian Z; Zhu H; Kong L; Wang P; Yu J
Target Oncol; 2016 Dec; 11(6):753-761. PubMed ID: 27422273
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Value of PD-L1 in Breast Cancer: A Meta-Analysis.
Wang C; Zhu H; Zhou Y; Mao F; Lin Y; Pan B; Zhang X; Xu Q; Huang X; Sun Q
Breast J; 2017 Jul; 23(4):436-443. PubMed ID: 28079291
[TBL] [Abstract][Full Text] [Related]
3. Role of programmed cell death ligand-1 expression on prognostic and overall survival of breast cancer: A systematic review and meta-analysis.
Li S; Chen L; Jiang J
Medicine (Baltimore); 2019 Apr; 98(16):e15201. PubMed ID: 31008945
[TBL] [Abstract][Full Text] [Related]
4. Predictive Values of Programmed Cell Death-Ligand 1 Expression for Prognosis, Clinicopathological Factors, and Response to Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Inhibitors in Patients With Gynecological Cancers: A Meta-Analysis.
Zhang C; Yang Q
Front Oncol; 2020; 10():572203. PubMed ID: 33634012
[TBL] [Abstract][Full Text] [Related]
5. PD-L1 expression and tumor infiltrating PD-1+ lymphocytes associated with outcome in HER2+ breast cancer patients.
Tsang JY; Au WL; Lo KY; Ni YB; Hlaing T; Hu J; Chan SK; Chan KF; Cheung SY; Tse GM
Breast Cancer Res Treat; 2017 Feb; 162(1):19-30. PubMed ID: 28058578
[TBL] [Abstract][Full Text] [Related]
6. Prognostic and clinicopathological value of PD-L1 in colorectal cancer: a systematic review and meta-analysis.
Yang L; Xue R; Pan C
Onco Targets Ther; 2019; 12():3671-3682. PubMed ID: 31190869
[No Abstract] [Full Text] [Related]
7. Clinicopathologic Significance and Prognostic Value of Programmed Cell Death Ligand 1 (PD-L1) in Patients With Hepatocellular Carcinoma: A Meta-Analysis.
Li JH; Ma WJ; Wang GG; Jiang X; Chen X; Wu L; Liu ZS; Zeng XT; Zhou FL; Yuan YF
Front Immunol; 2018; 9():2077. PubMed ID: 30254644
[No Abstract] [Full Text] [Related]
8. Prognostic and clinicopathological value of PD-L1 expression in primary breast cancer: a meta-analysis.
Huang W; Ran R; Shao B; Li H
Breast Cancer Res Treat; 2019 Nov; 178(1):17-33. PubMed ID: 31359214
[TBL] [Abstract][Full Text] [Related]
9. Expression of PD-L1 and prognosis in breast cancer: a meta-analysis.
Zhang M; Sun H; Zhao S; Wang Y; Pu H; Wang Y; Zhang Q
Oncotarget; 2017 May; 8(19):31347-31354. PubMed ID: 28430626
[TBL] [Abstract][Full Text] [Related]
10. Prognostic and Clinicopathological Value of Programmed Death Ligand-1 in Breast Cancer: A Meta-Analysis.
Guo Y; Yu P; Liu Z; Maimaiti Y; Wang S; Yin X; Liu C; Huang T
PLoS One; 2016; 11(5):e0156323. PubMed ID: 27227453
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of programmed cell death ligand 1 expression in patients with intrahepatic cholangiocarcinoma: a meta-analysis.
Xian F; Ren D; Bie J; Xu G
Front Immunol; 2023; 14():1119168. PubMed ID: 37138876
[TBL] [Abstract][Full Text] [Related]
12. The Association Between PD-L1 Expression and the Clinical Outcomes to Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma.
Shin SJ; Jeon YK; Cho YM; Lee JL; Chung DH; Park JY; Go H
Oncologist; 2015 Nov; 20(11):1253-60. PubMed ID: 26424759
[TBL] [Abstract][Full Text] [Related]
13. Prognostic and Clinicopathological Significance of PD-L1 in Patients With Bladder Cancer: A Meta-Analysis.
Zhu L; Sun J; Wang L; Li Z; Wang L; Li Z
Front Pharmacol; 2019; 10():962. PubMed ID: 31616289
[No Abstract] [Full Text] [Related]
14. Clinicopathological and prognostic significance of programmed death ligand-1 expression in breast cancer: a meta-analysis.
Kim HM; Lee J; Koo JS
BMC Cancer; 2017 Oct; 17(1):690. PubMed ID: 29041905
[TBL] [Abstract][Full Text] [Related]
15. Increased programmed death ligand-1 expression predicts poor prognosis in hepatocellular carcinoma patients.
Gu X; Gao XS; Xiong W; Guo W; Han L; Bai Y; Peng C; Cui M; Xie M
Onco Targets Ther; 2016; 9():4805-13. PubMed ID: 27536144
[TBL] [Abstract][Full Text] [Related]
16. Prognostic effect of programmed death-ligand 1 (PD-L1) in ovarian cancer: a systematic review, meta-analysis and bioinformatics study.
Wang L
J Ovarian Res; 2019 Apr; 12(1):37. PubMed ID: 31039792
[TBL] [Abstract][Full Text] [Related]
17. The prevalence and prognostic and clinicopathological value of PD-L1 and PD-L2 in renal cell carcinoma patients: a systematic review and meta-analysis involving 3,389 patients.
Lu Y; Song Y; Xu Y; Ou N; Liang Z; Hu R; Zhang W; Kang J; Wang X; Liu L; Yang Y; Liu X
Transl Androl Urol; 2020 Apr; 9(2):367-381. PubMed ID: 32420142
[TBL] [Abstract][Full Text] [Related]
18. Programmed cell death 1 (PD-1) receptor and programmed death ligand 1 (PD-L1) gene expression in primary breast cancer.
Vidula N; Yau C; Rugo HS
Breast Cancer Res Treat; 2021 Jun; 187(2):387-395. PubMed ID: 33913053
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Implications of Tumor-Infiltrating Lymphocytes in Association With Programmed Death Ligand 1 Expression in Early-Stage Breast Cancer.
Park IH; Kong SY; Ro JY; Kwon Y; Kang JH; Mo HJ; Jung SY; Lee S; Lee KS; Kang HS; Lee E; Joo J; Ro J
Clin Breast Cancer; 2016 Feb; 16(1):51-8. PubMed ID: 26364145
[TBL] [Abstract][Full Text] [Related]
20. The clinicopathological and prognostic value of programmed death-ligand 1 in colorectal cancer: a meta-analysis.
Ni X; Sun X; Wang D; Chen Y; Zhang Y; Li W; Wang L; Suo J
Clin Transl Oncol; 2019 May; 21(5):674-686. PubMed ID: 30392153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
